Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Characterization of Neurocognitive Profiles in Neurodevelopmental Disorders and Epilepsy: a Transdiagnostic Approach

NCT06877260 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-11-01
Last updated
2025-03-14

Condition(s) studied

Neurodevelopmental Disorder (Diagnosis)Epilepsy

Investigational drug(s) / intervention(s)

Computer based task with EEG

Computer based task with EEG: Participants will undergo EEG recording while performing a computer based neuropsychological task evaluating cognitive control

Study summary

Neurodevelopmental disorders (NDDs) are early-onset conditions affecting personal, social, and academic functioning, with high comorbidity rates and shared neurobiological traits. Traditional diagnostic categories struggle to explain symptom overlap, supporting a transdiagnostic approach that views NDDs as dimensions rather than distinct entities.

This project aims to identify common neuropsychological and neurophysiological profiles in ADHD, autism, intellectual disability, and learning disorders using high-density EEG and cognitive tasks assessing cognitive control. By integrating neuropsychological assessments, EEG responses, and behavioral data, the study seeks to identify shared functional profiles rather than disorder-specific biomarkers.

Additionally, it will analyze the relationship between NDDs and epilepsy to validate behavioral and neurophysiological markers. Conducted in collaboration with the University of Padua, the study employs advanced data analysis to enhance personalized interventions.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 6 and 16 years at the time of the study assessment. * Participant's ability to collaborate in performing computerized cognitive tasks. * Ability to undergo a neuropsychological assessment in the Italian language Exclusion Criteria: * Presence of organic disorders such as previous ischemic events, cerebral neoplastic elements, or a clinical history including brain surgery. * Age outside the 6-16 years range. * Inability to perform computerized cognitive tasks. * Inability to undergo a neuropsychological assessment in the Italian language.

Primary outcome measure(s)

  • EEG amplitude variation — Through study completion, an average of 1 year
    EEG evoked potentials amplitude measured in micronvolt

Trial sites (1)

FacilityCityRegionStatus
IRCC E.Medea Conegliano Italy/Treviso
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06877260 on ClinicalTrials.gov ↗ ← All trials in Italy